Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

NCT00785291 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

799

Enrollment

NIH

Sponsor class

Conditions

Estrogen Receptor Negative
Estrogen Receptor Positive
HER2/Neu Negative
HER2/Neu Positive
Progesterone Receptor Negative
Progesterone Receptor Positive
Recurrent Breast Carcinoma
Stage IIIC Breast Cancer AJCC v6
Stage IV Breast Cancer AJCC v6 and v7

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Ixabepilone
OTHER: Laboratory Biomarker Analysis
DRUG: Nab-paclitaxel
DRUG: Paclitaxel
OTHER: Questionnaire Administration

Sponsor

National Cancer Institute (NCI)